Karyopharm Therapeutics(US:KPTI)2026-02-13 01:38Financial Performance - As of December 31, 2025, the company had an accumulated deficit of $1.8 billion and net losses of $196.0 million, $76.4 million, and $143.1 million for the years ended December 31, 2025, 2024, and 2023, respectively[22]. - Total revenue recognized in 2025 was $146.1 million, which included $114.9 million from XPOVIO net product revenue and $31.2 million from license revenue[22]. - The company had $63.7 million in cash, cash equivalents, and investments as of December 31, 2025, raising substantial doubt about its ability to continue as a going concern within one year[22]. Strategic Focus - The strategy focuses on maximizing the commercial value of XPOVIO in multiple myeloma and expanding its use across therapy lines in the relapsed/refractory setting[23]. - The company aims to preserve capital and enhance its balance sheet to execute core objectives while managing capital resources effectively[23]. Clinical Pipeline and Trials - The clinical pipeline is prioritized to target cancers with high unmet needs, including myelofibrosis and endometrial cancer, with a focus on advancing late-stage clinical programs[23]. - Selinexor and eltanexor are being evaluated in multiple late-stage clinical trials for hematological and solid tumor malignancies, with ongoing investigator-sponsored trials[32]. - The pivotal Phase 3 SENTRY Trial for selinexor has completed enrollment with 353 JAKi-naive patients, and top-line data is expected to be reported in March 2026[39]. - The SENTRY-2 Trial is enrolling approximately 58 patients, with a primary endpoint of SVR35 at week 24[42]. - In the MF-035 Trial, 67% of selinexor treated patients achieved SVR25 or greater compared to 38% in the physician's choice group[45]. - The ESSENTIAL Trial showed that 27% of patients achieved SVR35 after at least 24 weeks of selinexor treatment[46]. - The XPORT-EC-042 Trial aims to enroll approximately 276 patients with TP53 wild-type tumors, with a primary endpoint of progression-free survival[53]. - The SIENDO Trial evaluated selinexor as maintenance therapy, with a primary endpoint of progression-free survival from randomization[54]. - The median overall survival in the ESSENTIAL Trial was 35 months, compared to a historical survival of 13 to 14 months in this population[46]. - In the SIENDO Trial, selinexor-treated patients had a median progression-free survival (PFS) of 5.7 months compared to 3.8 months for placebo, representing a 50% improvement[55]. - Updated data from the SIENDO Trial showed selinexor-treated patients with TP53 wild-type advanced or recurrent endometrial cancer had a median PFS of 28.4 months versus 5.2 months for placebo, with a hazard ratio (HR) of 0.44[56]. - The BOSTON Trial demonstrated a median PFS of 13.9 months for the XVd Arm compared to 9.5 months for the Vd Arm, indicating a 47% increase in PFS[61]. - In the BOSTON Trial, the overall response rate (ORR) for the XVd Arm was 76.4% compared to 62.3% for the Vd Arm[61]. - The STORM Trial reported an ORR of 26% for selinexor in combination with dexamethasone, with a median duration of response (DOR) of 4.4 months[66]. - The EMN29 Trial enrolled 117 patients to evaluate selinexor in combination with pomalidomide and dexamethasone versus elotuzumab, with primary endpoint being PFS[69]. - The EMN29 Trial's design was amended to reduce target enrollment from 222 to approximately 120 patients due to slower than expected patient enrollment[71]. - The STOMP Trial indicated a median PFS of 18.4 months for the SPd regimen, influencing the design of the EMN29 Trial[71]. - The SADAL Trial demonstrated an ORR of 29% for selinexor in patients with relapsed or refractory DLBCL, with a complete response (CR) rate of 13% and a median duration of response (DOR) of 9.3 months[74]. - The XPORT-DLBCL-030 Trial is currently in Phase 2, evaluating the combination of selinexor and R-GDP, with primary endpoint being progression-free survival (PFS)[76]. Partnerships and Agreements - The company received an upfront cash payment of $75 million from Menarini in December 2021 and an additional $3.5 million in April 2023 under the Menarini Agreement[84]. - From 2022 to 2025, Menarini reimbursed the company for 25% of development expenses up to $15 million per year, totaling $15 million in reimbursements for the year ended December 31, 2025[84]. - The Amended Antengene Agreement provided the company with an upfront payment of $11.7 million in June 2020, with additional milestone payments and tiered royalties based on net sales in the Antengene Territory[87]. - The company entered into an exclusive distribution agreement with FORUS for XPOVIO in Canada, receiving an upfront payment of $5 million and eligible for double-digit royalties on net sales[88]. - The company has retained exclusive production rights for XPOVIO while FORUS is responsible for regulatory filings in Canada[88]. Intellectual Property - As of February 5, 2026, the company holds 53 patents in the U.S. and has 13 pending patent applications, along with 189 granted patents and 79 pending applications in foreign jurisdictions[93][94]. - The patent portfolio includes significant coverage for selinexor, with two U.S. patents expiring in July 2032 and July 2033, and additional patents expiring no earlier than August 2035[99]. - The company has filed applications for Supplementary Protection Certificates in Europe for selinexor, with some applications granted and others pending[99]. - The patent term for selinexor has been extended by 342 days in the U.S., 150 days in Korea, and 5 years in Taiwan, with an extension in Australia from July 26, 2032, to March 8, 2037[100]. Competitive Landscape - The company faces competition from major pharmaceutical and biotechnology companies, with several other XPO1 inhibitors in clinical development globally[105][106]. - The competitive landscape includes multiple therapies for myelofibrosis, with only four JAK inhibitors currently approved, and ongoing clinical trials for alternative treatments[113][114]. - The treatment landscape for endometrial cancer has evolved significantly since 2023, with new combination therapies available, but no specific targeted FDA-approved therapies for TP53 wild-type cases[115]. - XPOVIO is the only XPO1 inhibitor with marketing approval, competing against various treatment types for multiple myeloma[116]. - XPOVIO is competing in the multiple myeloma market against established therapies such as IMiDs and PIs, with new bispecific T-cell engagers like TECVAYLI® approved in October 2022 and others expected in 2026 and beyond[117]. Sales and Marketing - The sales team consists of approximately 60 field-based employees focused on educating healthcare providers about XPOVIO, with plans for potential expansion to support future product launches[121]. - The KaryForward® patient support program assists eligible patients with insurance coverage issues, offering copay cards that reduce prescription costs to as low as $5.00[123]. Manufacturing and Supply Chain - XPOVIO's manufacturing relies on third-party contract manufacturers, with all global supplies produced in the U.S. to ensure quality and reliability[124]. - The company maintains sufficient inventory levels to exceed two-year forecasts for XPOVIO, minimizing supply disruption risks[126]. - Regulatory compliance is critical, with substantial time and financial resources required for drug development and approval processes[128]. Regulatory Environment - The FDA's approval process includes multiple steps, such as preclinical studies, IND submission, and clinical trials, which must comply with stringent regulations[131]. - The FDA requires sponsors to submit amendments for new protocols or changes to existing protocols before implementation[138]. - Clinical trials may be suspended or terminated if participants are exposed to unacceptable health risks or due to evolving business objectives[139]. - Foreign clinical trials must comply with FDA regulations and GCP standards to be considered valid for U.S. marketing approval[140]. - The FDA will not accept foreign trial data as the sole basis for approval unless specific conditions are met, including applicability to the U.S. population[141]. - Sponsors must register and disclose clinical trial information on clinicaltrials.gov, with results required to be disclosed within two years post-completion[143]. - The FDA has issued six notices of non-compliance for failure to submit required clinical trial information, with potential penalties of up to $10,000 per day[144]. - Expanded access allows investigational drugs to be used outside of clinical trials for patients with serious conditions when no alternatives exist[145]. - The Right to Try Act allows certain patients to access investigational products post-Phase I trials without FDA permission[147]. - The FDA requires sponsors to develop and submit diversity action plans for Phase 3 clinical trials to encourage diverse patient enrollment[155]. - The FDA issued draft guidance in June 2023 aimed at modernizing GCPs to facilitate more efficient clinical trials[156]. - The FDA's 2024 guidance indicates that companion diagnostic devices used in clinical trials are generally considered investigational unless already approved, requiring compliance with IDE regulations[162]. - The PMA process for in vitro companion diagnostics can take several years, with a standard application fee of $540,783 and a small business fee of $135,196 for federal fiscal year 2025[166]. - The FDA mandates that medical devices, including diagnostics, must be marketed only for approved uses, and manufacturers must comply with Quality System Regulation[167]. - The Pediatric Research Equity Act requires pediatric data for products intended for use in children, with initial Pediatric Study Plans due within 60 days of an EOP2 meeting[170]. - The FDA can grant Fast Track designation for products addressing unmet medical needs, allowing for greater interaction and rolling review of applications[174]. - Breakthrough Therapy designation may be granted if preliminary evidence shows substantial improvement over existing therapies, facilitating more efficient clinical trial designs[175]. - Priority Review designation shortens the FDA's review time from ten months to six months for products that significantly improve safety or effectiveness[177]. - The accelerated approval pathway allows drugs to be approved based on surrogate endpoints, with a requirement for post-approval confirmatory studies[179]. - New legislation in December 2022 allows the FDA to require confirmatory trials to be underway before granting accelerated approval and mandates progress reports every six months[183]. - The FDA's application fee for NDA submission in federal fiscal year 2025 is $4,310,002, with an annual program fee of $403,889 per eligible prescription product[187]. - The standard review time for an initial NDA is 12 months, while a supplemental application takes 10 months[187]. - The FDA conducts a preliminary review within 60 days of receipt to determine if the application is sufficiently complete for substantive review[188]. - A Complete Response Letter (CRL) indicates that the application will not be approved in its current form, outlining deficiencies that may require substantial additional testing[198]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits of a product outweigh its risks[194]. - The FDA has ten months from the filing date to complete its initial review of a standard application, with a potential three-month extension for new information[189]. - The FDA may refer applications to an advisory committee for review, although it is not bound by their recommendations[193]. - Post-approval, drugs are subject to ongoing regulation, including recordkeeping and reporting of adverse experiences[201]. - The FDA may withdraw approval if compliance with regulatory requirements is not maintained after market entry[203]. - The FDA published draft guidance in October 2023 regarding non-promotional communication of unapproved uses to healthcare providers, which was finalized on January 6, 2025[205]. - The FDA has established a ten-year phase-in process for the Drug Supply Chain Security Act, requiring manufacturers to implement electronic systems for tracing prescription drugs by November 2023[207]. - The FDA provides a five-year regulatory exclusivity period for new drugs containing a new chemical entity, preventing ANDA or 505(b)(2) applications until this period expires[213]. - A three-year exclusivity period is granted if the NDA includes reports of new clinical trials essential for approval, protecting changes to previously approved drug products[214]. - The FDA must review certain generic drug applications within eight months if there are three or fewer approved drugs listed in the Orange Book, expediting the approval process[215]. - The Paragraph IV certification allows ANDA sponsors to challenge existing patents, potentially delaying FDA approval for up to 30 months if a lawsuit is filed[219]. - Orphan Drug Designation encourages the development of products for rare diseases affecting fewer than 200,000 individuals in the U.S.[221]. - Section 505(b)(2) NDAs can expedite FDA approval by allowing reliance on previous findings of safety and efficacy for similar products[208]. - The FDA may require additional studies to support changes from approved products under Section 505(b)(2)[210]. - The FDA's designation of therapeutic equivalence allows for substitution of generic drugs without clinician or patient consent, impacting market dynamics[212]. - Companies may face significant penalties, including fines and injunctions, for improper promotion of drug products, affecting their commercial operations[209].